✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals
Market Cap
₹25,927 Cr.
P/E
284.51

Key Ratios

Market cap
Market cap
25,927 Cr
PE
PE
284
Prom Holding
Prom Holding
34.95 %
ROE (%)
ROE (%)
0.23
ROCE (%)
ROCE (%)
5.82
Div Yield (%)
Div Yield (%)
0.13
Sales
Sales
9,151 Cr
OPM (%)
OPM (%)
15.79 %
Debt to Equity
Debt to Equity
0.58
About
Piramal Pharma Limited (PPL) provides a wide range of products and services globally through v… Read more
Low
145
52W Range
High
308
  • Piramal Pharma
  • Cohance Lifesciences
  • Suven Life Sciences

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statementNew
Edit rows
Forensics

9 Yes

Positive for this company

1 Neutral

Neutral for this company

5 No

Negative for this company

2 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Verticals - Development

Location Wise Break-Up

Services Break-Up

Operational Metrics

    Select a Metric
    • Domestic Sales Growth - YoY (%)
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Corporate Actions
    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less
    FAQs on Piramal Pharma Ltd. Business

    Piramal Pharma Limited provides a range of products and services through global manufacturing capabilities and distribution networks. Its offerings include integrated Contract Development and Manufacturing, Complex Hospital Generics, and Consumer Healthcare products across multiple countries.

    Piramal Pharma major competitors are Cohance Lifesciences, Suven Life Sciences, Hikal, Syngene Internation., Sun Pharma Adv. Res, Dishman Carbogen Amc, Zenotech Laboratorie.
    Market Cap of Piramal Pharma is ₹25,927 Crs.
    While the median market cap of its peers are ₹5,169 Crs.

    Piramal Pharma seems to be less financially stable compared to its competitors.
    Altman Z score of Piramal Pharma is 3.38 and is ranked 7 out of its 8 competitors.

    Company Filing
    2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release May Mar Jun Sep Dec Mar Jun Sep Dec Sep Dec
    Investor Presentation May Mar Jun Sep Dec Mar Jun Sep Dec Mar Sep Dec
    Conference Call Mar Mar Jun Sep Dec Mar Jun Sep Dec Sep Dec
    Conference Call SummaryCon Call Summary
    Discussions & Analysis
    Piramal Pharma Ltd.
    Ideas Dashboard
    Timeline
    Watchlist
    Portfolio
    Alerts
    Research
    Stock Screener
    Market
    Raw Material